I. Landry

发表

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors

E. Schuck, Bojan Lalovic, Takashi Ueno, 2021, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

A. Koyama, C. Swanson, S. Hayato, 2022, CPT: pharmacometrics & systems pharmacology.

ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies

B. Darpo, M. Borin, G. Ferber, 2022, Journal of clinical pharmacology.

Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection.

Naiyu Zheng, M. Arnold, A. Aubry, 2016, Analytica chimica acta.

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females

M. Moline, J. Aluri, G. Filippov, 2021, Clinical pharmacology in drug development.

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

Samit R. Joshi, B. Sadler, R. Bertz, 2016, Antimicrobial Agents and Chemotherapy.

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users

J. Henningfield, B. Setnik, M. Moline, 2022, Journal of clinical psychopharmacology.

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults

J. Ferry, M. Moline, J. Aluri, 2020, Clinical pharmacology in drug development.

Subcutaneous Dose Selection of Lecanemab for Treatment of Subjects with Early Alzheimer’s Disease (EAD)

P. Boyd, J. Aluri, B. Willis, 2022, Alzheimer's & Dementia.

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Pharmacology research & perspectives.

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

M. Moline, J. Aluri, O. Majid, 2020, Journal of clinical pharmacology.

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Clinical pharmacology in drug development.

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

C. V. Van Leeuwen, J. Ramaekers, E. Vuurman, 2018, Sleep.

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027

E. Schuck, P. Boyd, J. Aluri, 2022, Alzheimer disease and associated disorders.

E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies

B. Darpo, J. Aluri, Hongqi Xue, 2022, Alzheimer disease and associated disorders.

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act

J. Henningfield, B. Setnik, M. Moline, 2023, Psychopharmacology.

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

M. Moline, J. Aluri, G. Filippov, 2021, Pharmacology research & perspectives.